Search results
Results from the WOW.Com Content Network
Ovarian cancer usually has a relatively poor prognosis. It is disproportionately deadly because it lacks any clear early detection or screening test, meaning most cases are not diagnosed until they have reached advanced stages. [123] [28] Ovarian cancer metastasizes early in its development, often before it has been diagnosed.
A panel of epigenetic methylation marker has been explored for prognosis of ovarian cancer, and it is reported that the panel exhibited high specificity and sensitivity (both above 70%) as a screen marker. [5] Epigenetic markers have also shown promising potential as prognostic markers for bladder cancer. [6]
The spread of OGCT is identified through different stages: stage I, stage II, stage III, and stage IV namely. Stage I: Tumor cells are localized in the ovaries or the fallopian tubes without extensive spread to other body regions. [22] Stage II: The cancer is in one or both ovaries or fallopian tubes and has spread into the pelvis. [22]
There are also a “huge number” of interactions likely occurring between the brain and the ovaries throughout a woman’s life, Garrison says, but “we don’t know all the words in that ...
Reflect the stage of cancer; By determining the stage of cancer, it's possible to give a prognosis and treatment plan. [4] Screening for cancers; No screening test is wholly specific, and a high level of tumor marker can still be found in benign tumors. The only tumor marker currently used in screening is PSA (prostate-specific antigen ...
Gynecologic cancer is a type of cancer that affects the female reproductive system, including ovarian cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer. Gynecological cancers comprise 10-15% of women's cancers, mainly affecting women past reproductive age but posing threats to fertility for younger patients. [ 1 ]
Ovarian squamous cell carcinoma (oSCC) or squamous ovarian carcinoma (SOC) is a rare tumor that accounts for 1% of ovarian cancers. [1] Included in the World Health Organization 's classification of ovarian cancer, [ 2 ] it mainly affects women above 45 years of age.
Altered brain structure in chemotherapy patients provides explanation for cognitive impairment. [12] Another study in 2007 investigated the differences in brain structure between two adult, monozygotic twin females. One underwent chemotherapy treatment for breast cancer, while the other did not have cancer and was not treated with chemotherapy.